Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2020 · 10-Q
Revenue$4.50M$4.50M+2.9% vs Q1 2019 Net Income$715.00K$715.00KN/M vs Q1 2019 EPS Diluted$0.54$0.54N/M vs Q1 2019 Gross Profit$2,293,000+32.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow$738,000N/M Free Cash Flowderived$726,000N/M Margins · derivedGross margin51.0%+11.4 pt vs Q1 2019
Operating margin-39.4%+41.9 pt vs Q1 2019
Net margin15.9%+95.1 pt vs Q1 2019
ended Jun 30, 2019 · filed Aug 13, 2019 · 44 d after period end